Rentokil's 2025 H1 meets expectations with 31% cash flow surge & early North American recovery signs. Steady operational progress delivered.
This article covers information on Rentokil Initial PLC.
LON:RTORentokil Initial’s 2025 interim results land precisely where expected – no fireworks, but a steady performance underscored by robust cash flow and strategic progress. The pest control and hygiene giant posted group revenue growth of 3.1% (constant currency) to $3.36bn, with adjusted operating profit at $511m. While profit margins saw some pressure, the standout story is free cash flow leaping 31% to $282m, converting at an impressive 93% – well ahead of their 80% guidance. That’s the kind of financial muscle that keeps investors nodding approvingly.
Let’s cut straight to the hero metric: free cash flow. Generating $282m in H1 (up $67m year-on-year) speaks volumes about operational discipline. This wasn’t magic; it stemmed from:
This performance gives Rentokil significant flexibility. With the France Workwear sale (€370m net proceeds expected late Q3/early Q4) set to further slash debt and reduce annual capex by ~$100m, the balance sheet looks increasingly sturdy, even with net debt at $4.22bn (2.8x adjusted EBITDA).
All eyes remain on North America post-Terminix. While revenue grew 2.0% ($2.11bn), adjusted operating profit dipped 7.3%, and margins contracted 170bps to 16.9%. Volume challenges linger, but the crucial narrative is one of gathering momentum:
The integration playbook is being refined. H2 will see migration restart for standalone commercial branches and targeted improvements in underperforming migrated branches. While the $100m cost synergy target and ambition for >20% NA margins post-2026 stand firm, CEO Andy Ransom flags that “refined timelines may mean not all branches are fully integrated by that time”. Realism, not retreat.
While North America grabs headlines, the International segment (Europe, UK, Asia, Pacific) delivered reliably strong results:
Related
Polar Capital Technology Trust sees 102% NAV growth in FY2026, beating its benchmark by 47 points thanks to AI and semiconductor exposure.
JoshuaJuly 10, 2026
Last updated
Category
InvestingViews
96 viewsLikes
No ratings yet
It’s a reminder of the diversified engine beneath the group.
Pest Control (79% of Group Revenue): Revenue up 2.9% ($2.79bn), driven by International. Smart tech roll-out continues – 106k new PestConnect devices installed, AI-enabled PestConnect Optix now live in multiple markets, with Lumnia Optix (digital insect traps) piloting.
Hygiene & Wellbeing (17% of Group Revenue): Revenue up 4.3% ($566m), primarily from pricing. Margins held flat at 17.2% despite cost inflation, showcasing solid operational control.
Beyond integration, key strategic strides include:
The outlook is straightforward: “Current trading is in line with expectations and our outlook for the remainder of the year remains unchanged. We expect to deliver FY25 results in line with market expectations.” Confidence, quietly stated.
Rentokil’s H1 isn’t about explosive growth; it’s about delivering on promises and demonstrating operational resilience. Hitting expectations, generating exceptional cash flow, and showing tangible signs of improvement in the crucial North American market are the key takeaways. The integration journey is complex and timelines might flex, but the destination ($100m savings, >20% NA margins) remains fixed. The maintained dividend (4.15 cents) is a nod to stability. For investors, it’s a case of ‘steady as she goes’, underpinned by that powerful cash conversion. The real test remains executing the North American turnaround – but the green shoots in lead flow suggest the seeds are finally starting to sprout.
Impax Q3 AUM rises to £23.3bn despite £1.7bn net outflows, driven by market gains and strong investment performance.
JoshuaJuly 10, 2026
MJ Gleeson FY2026 trading update: steady profits, mixed home sales with operational restructuring improving outlook.
JoshuaJuly 10, 2026
No comments yet - start the conversation.